Can ceftolozane-tazobactam treat nosocomial pneumonia?

Affiliations

¹ Division of Infectious Diseases, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE 68198, USA. Electronic address: akalil@unmc.edu.
² Department of Internal Medicine, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil; Infectious Diseases Service, Hospital Moinhos de Vento, Porto Alegre, Brazil; Infectious Diseases Service, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.

Comment

Andre C Kalil et al. Lancet Infect Dis. 2019 Dec.

. 2019 Dec;19(12):1266-1267.

doi: 10.1016/S1473-3099(19)30523-7. Epub 2019 Sep 25.

¹ Division of Infectious Diseases, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE 68198, USA. Electronic address: akalil@unmc.edu.
² Department of Internal Medicine, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil; Infectious Diseases Service, Hospital Moinhos de Vento, Porto Alegre, Brazil; Infectious Diseases Service, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.

No abstract available

Comment on

Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial.
Kollef MH, Nováček M, Kivistik Ü, Réa-Neto Á, Shime N, Martin-Loeches I, Timsit JF, Wunderink RG, Bruno CJ, Huntington JA, Lin G, Yu B, Butterton JR, Rhee EG. Kollef MH, et al. Lancet Infect Dis. 2019 Dec;19(12):1299-1311. doi: 10.1016/S1473-3099(19)30403-7. Epub 2019 Sep 25. Lancet Infect Dis. 2019. PMID: 31563344 Clinical Trial.